Outcomes and Therapeutic Management of Bladder Cancer
Bladder cancer is the second most common genitourinary malignancy, with 81,190 estimated new diagnoses in 2018, in the United States alone. Transurethral resection of the bladder and radical cystectomy with bilateral pelvic lymph node dissection constitute the standard treatment for non-muscle invas...
Saved in:
| Other Authors: | |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel, Switzerland
MDPI - Multidisciplinary Digital Publishing Institute
2020
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_69079 | ||
| 005 | 20210501 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20210501s2020 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-03936-935-5 | ||
| 020 | |a 9783039369348 | ||
| 020 | |a 9783039369355 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-03936-935-5 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 100 | 1 | |a Moschini, Marco |4 edt | |
| 700 | 1 | |a Moschini, Marco |4 oth | |
| 245 | 1 | 0 | |a Outcomes and Therapeutic Management of Bladder Cancer |
| 260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2020 | ||
| 300 | |a 1 electronic resource (120 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Bladder cancer is the second most common genitourinary malignancy, with 81,190 estimated new diagnoses in 2018, in the United States alone. Transurethral resection of the bladder and radical cystectomy with bilateral pelvic lymph node dissection constitute the standard treatment for non-muscle invasive or very high-risk non-muscle invasive bladder cancer, respectively. However, survival expectations have not shown to improve in the last 20 years, and new diagnostic and therapeutic tools are urgently needed to improve the outcomes of this potentially lethal disease. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a bladder cancer | ||
| 653 | |a robotic-assisted | ||
| 653 | |a open | ||
| 653 | |a radical cystectomy | ||
| 653 | |a survival | ||
| 653 | |a propensity score | ||
| 653 | |a age | ||
| 653 | |a urothelial carcinoma | ||
| 653 | |a outcome | ||
| 653 | |a anesthesia recovery periods | ||
| 653 | |a cognitive impairment | ||
| 653 | |a gamma-cyclodextrins | ||
| 653 | |a neuromuscular blockade | ||
| 653 | |a robotic radical cystectomy | ||
| 653 | |a glycogen | ||
| 653 | |a clear-cell adenocarcinoma | ||
| 653 | |a urinary bladder | ||
| 653 | |a SEER program database | ||
| 653 | |a female | ||
| 653 | |a intracorporeal neobladder | ||
| 653 | |a outcomes | ||
| 653 | |a robotic | ||
| 653 | |a sex-sparing | ||
| 653 | |a methylation | ||
| 653 | |a biomarkers | ||
| 653 | |a FOXA1 | ||
| 653 | |a GATA3 | ||
| 653 | |a KRT20 | ||
| 653 | |a molecular markers | ||
| 653 | |a mRNA | ||
| 653 | |a muscle-invasive bladder cancer | ||
| 653 | |a PCR | ||
| 653 | |a human epidermal growth factor receptor 2 | ||
| 653 | |a indoleamine 2,3-dioxygenase | ||
| 653 | |a programmed death ligand-1 | ||
| 653 | |a immunotherapy | ||
| 653 | |a nodal disease | ||
| 653 | |a pN1 | ||
| 653 | |a neoadjuvant | ||
| 653 | |a adjuvant | ||
| 653 | |a chemotherapy | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/2848 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/69079 |7 0 |z DOAB: description of the publication |